Novartis's Cosentyx Climbs Despite Competitors And COVID-19

First Billion Dollar Quarter For Anti-IL-17 Blockbuster

 
• By Kevin Grogan
  
Vas Narasimhan
Vas Narasimhan: Confident About Cosentyx Growth • Source: Novartis

More from Earnings

More from Business